{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T15:42:45Z","timestamp":1793720565292,"version":"4.6.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science","award":["22K08553"],"award-info":[{"award-number":["22K08553"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-10895-1","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T10:42:28Z","timestamp":1752576148000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Dysregulated type I\/III interferon system in circulation from patients with anti-MDA5-positive dermatomyositis"],"prefix":"10.1038","volume":"15","author":[{"given":"Akira","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Gono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masumi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kitahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoji","family":"Yokobori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimpei","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8352-6136","authenticated-orcid":false,"given":"Masataka","family":"Kuwana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"10895_CR1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","volume":"7","author":"IE Lundberg","year":"2021","unstructured":"Lundberg, I. E. et al. Idiopathic inflammatory myopathies. Nat. Rev. Dis. Primers. 7, 86. https:\/\/doi.org\/10.1038\/s41572-021-00321-x (2021).","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10895_CR2","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","volume":"14","author":"NJ McHugh","year":"2018","unstructured":"McHugh, N. J. & Tansley, S. L. Autoantibodies in myositis. Nat. Rev. Rheumatol. 14, 290\u2013302. https:\/\/doi.org\/10.1038\/nrrheum.2018.56 (2018).","journal-title":"Nat. Rev. Rheumatol."},{"key":"10895_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41584-024-01188-4","volume":"21","author":"NA Allameen","year":"2025","unstructured":"Allameen, N. A., Ramos-Lisbona, A. I., Wedderburn, L. R., Lundberg, I. E. & Isenberg, D. A. An update on autoantibodies in the idiopathic inflammatory myopathies. Nat. Rev. Rheumatol. 21, 46\u201362. https:\/\/doi.org\/10.1038\/s41584-024-01188-4 (2025).","journal-title":"Nat. Rev. Rheumatol."},{"key":"10895_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11926-024-01171-8","volume":"27","author":"GR Harvey","year":"2024","unstructured":"Harvey, G. R., MacFadyen, C. & Tansley, S. L. Newer autoantibodies and laboratory assessments in myositis. Curr. Rheumatol. Rep. 27, 5. https:\/\/doi.org\/10.1007\/s11926-024-01171-8 (2024).","journal-title":"Curr. Rheumatol. Rep."},{"key":"10895_CR5","doi-asserted-by":"publisher","first-page":"773352","DOI":"10.3389\/fimmu.2021.773352","volume":"12","author":"A Nombel","year":"2021","unstructured":"Nombel, A., Fabien, N. & Coutant, F. Dermatomyositis with anti-MDA5 antibodies: Bioclinical features, pathogenesis and emerging therapies. Front. Immunol. 12, 773352. https:\/\/doi.org\/10.3389\/fimmu.2021.773352 (2021).","journal-title":"Front. Immunol."},{"key":"10895_CR6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41584-023-01054-9","volume":"20","author":"X Lu","year":"2024","unstructured":"Lu, X., Peng, Q. & Wang, G. Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress. Nat. Rev. Rheumatol. 20, 48\u201362. https:\/\/doi.org\/10.1038\/s41584-023-01054-9 (2024).","journal-title":"Nat. Rev. Rheumatol."},{"key":"10895_CR7","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1093\/rheumatology\/key060","volume":"57","author":"S Sato","year":"2018","unstructured":"Sato, S. et al. Initial predictors of poor survival in myositis-associated interstitial lung disease: A multicentre cohort of 497 patients. Rheumatology 57, 1212\u20131221. https:\/\/doi.org\/10.1093\/rheumatology\/key060 (2018).","journal-title":"Rheumatology"},{"key":"10895_CR8","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/bor.0000000000001037","volume":"36","author":"T Gono","year":"2024","unstructured":"Gono, T. & Kuwana, M. Interstitial lung disease and myositis. Curr. Opin. Rheumatol. 36, 466\u2013472. https:\/\/doi.org\/10.1097\/bor.0000000000001037 (2024).","journal-title":"Curr. Opin. Rheumatol."},{"key":"10895_CR9","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1093\/rheumatology\/keu258","volume":"53","author":"T Gono","year":"2014","unstructured":"Gono, T. et al. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology 53, 2196\u20132203. https:\/\/doi.org\/10.1093\/rheumatology\/keu258 (2014).","journal-title":"Rheumatology"},{"key":"10895_CR10","doi-asserted-by":"publisher","first-page":"6458","DOI":"10.1038\/s41467-022-34145-4","volume":"13","author":"Y Ye","year":"2022","unstructured":"Ye, Y. et al. Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5+ dermatomyositis with therapeutic implications. Nat. Commun. 13, 6458. https:\/\/doi.org\/10.1038\/s41467-022-34145-4 (2022).","journal-title":"Nat. Commun."},{"key":"10895_CR11","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1093\/rheumatology\/kead597","volume":"63","author":"J He","year":"2024","unstructured":"He, J. et al. Single-cell landscape of peripheral immune response in patients with anti-melanoma differentiation-associated gene 5 dermatomyositis. Rheumatology 63, 2284\u20132294. https:\/\/doi.org\/10.1093\/rheumatology\/kead597 (2024).","journal-title":"Rheumatology"},{"key":"10895_CR12","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/rheumatology\/keab371","volume":"61","author":"T Gono","year":"2022","unstructured":"Gono, T., Okazaki, Y. & Kuwana, M. Antiviral proinflammatory phenotype of monocytes in anti-MDA5 antibody-associated interstitial lung disease. Rheumatology 61, 806\u2013814. https:\/\/doi.org\/10.1093\/rheumatology\/keab371 (2022).","journal-title":"Rheumatology"},{"key":"10895_CR13","doi-asserted-by":"publisher","first-page":"103420","DOI":"10.1016\/j.autrev.2023.103420","volume":"22","author":"J Thuner","year":"2023","unstructured":"Thuner, J. & Coutant, F. IFN-\u03b3: An overlooked cytokine in dermatomyositis with anti-MDA5 antibodies. Autoimmun. Rev. 22, 103420. https:\/\/doi.org\/10.1016\/j.autrev.2023.103420 (2023).","journal-title":"Autoimmun. Rev."},{"key":"10895_CR14","doi-asserted-by":"publisher","first-page":"2001618","DOI":"10.1183\/13993003.01618-2020","volume":"56","author":"M Giannini","year":"2020","unstructured":"Giannini, M. et al. Similarities between COVID-19 and anti-MDA5 syndrome: What can we learn for better care?. Eur. Respir. J. 56, 2001618. https:\/\/doi.org\/10.1183\/13993003.01618-2020 (2020).","journal-title":"Eur. Respir. J."},{"key":"10895_CR15","doi-asserted-by":"publisher","first-page":"e13808","DOI":"10.1111\/eci.13808","volume":"52","author":"T Suzuki","year":"2022","unstructured":"Suzuki, T. et al. Interferon lambda 3 in the early phase of coronavirus disease-19 can predict oxygen requirement. Eur. J. Clin. Invest. 52, e13808. https:\/\/doi.org\/10.1111\/eci.13808 (2022).","journal-title":"Eur. J. Clin. Invest."},{"key":"10895_CR16","doi-asserted-by":"publisher","first-page":"145145","DOI":"10.1016\/j.gene.2020.145145","volume":"766","author":"M Sugiyama","year":"2021","unstructured":"Sugiyama, M. et al. Serum CCL17 level becomes a predictive marker to distinguish between mild\/moderate and severe\/critical disease in patients with COVID-19. Gene 766, 145145. https:\/\/doi.org\/10.1016\/j.gene.2020.145145 (2021).","journal-title":"Gene"},{"key":"10895_CR17","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/art.42785","volume":"76","author":"A Fukada","year":"2024","unstructured":"Fukada, A. et al. Prognostic role of interferon-\u03bb3 in anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated interstitial lung disease. Arthritis Rheumatol. 76, 796\u2013805. https:\/\/doi.org\/10.1002\/art.42785 (2024).","journal-title":"Arthritis Rheumatol."},{"key":"10895_CR18","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","volume":"76","author":"IE Lundberg","year":"2017","unstructured":"Lundberg, I. E. et al. 2017 European league against rheumatism\/american college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann. Rheum. Dis. 76, 1955\u20131964. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211468 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"10895_CR19","doi-asserted-by":"publisher","first-page":"1529582","DOI":"10.3389\/fimmu.2025.1529582","volume":"16","author":"L Bolko","year":"2025","unstructured":"Bolko, L. et al. Ultrasensitive interferons quantification reveals different cytokine profile secretion in inflammatory myopathies and can serve as biomarkers of activity in dermatomyositis. Front. Immunol. 16, 1529582. https:\/\/doi.org\/10.3389\/fimmu.2025.1529582 (2025).","journal-title":"Front. Immunol."},{"key":"10895_CR20","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1093\/rheumatology\/kez525","volume":"59","author":"I Melki","year":"2020","unstructured":"Melki, I. et al. Anti-MDA5 juvenile idiopathic inflammatory myopathy: A specific subgroup defined by differentially enhanced interferon-\u03b1 signaling. Rheumatology 59, 1927\u20131937. https:\/\/doi.org\/10.1093\/rheumatology\/kez525 (2020).","journal-title":"Rheumatology"},{"key":"10895_CR21","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1212\/wnl.0000000000009727","volume":"95","author":"Y Allenbach","year":"2020","unstructured":"Allenbach, Y. et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: Study of 121 cases. Neurology 95, e70\u2013e78. https:\/\/doi.org\/10.1212\/wnl.0000000000009727 (2020).","journal-title":"Neurology"},{"key":"10895_CR22","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/ni.3212","volume":"16","author":"A Wack","year":"2015","unstructured":"Wack, A., Terczy\u0144ska-Dyla, E. & Hartmann, R. Guarding the frontiers: The biology of type III interferons. Nat. Immunol. 16, 802\u2013809. https:\/\/doi.org\/10.1038\/ni.3212 (2015).","journal-title":"Nat. Immunol."},{"key":"10895_CR23","doi-asserted-by":"publisher","first-page":"764062","DOI":"10.3389\/fimmu.2021.764062","volume":"12","author":"S Manivasagam","year":"2021","unstructured":"Manivasagam, S. & Klein, R. S. Type III interferons: Emerging roles in autoimmunity. Front. Immunol. 12, 764062. https:\/\/doi.org\/10.3389\/fimmu.2021.764062 (2021).","journal-title":"Front. Immunol."},{"key":"10895_CR24","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41584-021-00606-1","volume":"17","author":"RR Goel","year":"2021","unstructured":"Goel, R. R., Kotenko, S. V. & Kaplan, M. J. Interferon lambda in inflammation and autoimmune rheumatic diseases. Nat. Rev. Rheumatol. 17, 349\u2013362. https:\/\/doi.org\/10.1038\/s41584-021-00606-1 (2021).","journal-title":"Nat. Rev. Rheumatol."},{"key":"10895_CR25","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","volume":"51","author":"T Gono","year":"2012","unstructured":"Gono, T. et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology 51, 1563\u20131570. https:\/\/doi.org\/10.1093\/rheumatology\/kes102 (2012).","journal-title":"Rheumatology"},{"key":"10895_CR26","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1111\/j.1872-034X.2012.01032.x","volume":"42","author":"M Sugiyama","year":"2012","unstructured":"Sugiyama, M. et al. Development of specific and quantitative real-time detection PCR and immunoassays for \u03bb3-interferon. Hepatol. Res. 42, 1089\u20131099. https:\/\/doi.org\/10.1111\/j.1872-034X.2012.01032.x (2012).","journal-title":"Hepatol. Res."},{"key":"10895_CR27","doi-asserted-by":"publisher","first-page":"1151695","DOI":"10.3389\/fimmu.2023.1151695","volume":"14","author":"J Qian","year":"2023","unstructured":"Qian, J. et al. Type I interferon score is associated with the severity and poor prognosis in anti-MDA5 antibody-positive dermatomyositis patients. Front. Immunol. 14, 1151695. https:\/\/doi.org\/10.3389\/fimmu.2023.1151695 (2023).","journal-title":"Front. Immunol."},{"key":"10895_CR28","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.immuni.2019.03.025","volume":"50","author":"HM Lazear","year":"2019","unstructured":"Lazear, H. M., Schoggins, J. W. & Diamond, M. S. Shared and distinct functions of type I and type III interferons. Immunity 50, 907\u2013923. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.025 (2019).","journal-title":"Immunity"},{"key":"10895_CR29","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41577-019-0182-z","volume":"19","author":"L Ye","year":"2019","unstructured":"Ye, L., Schnepf, D. & Staeheli, P. Interferon-\u03bb orchestrates innate and adaptive mucosal immune responses. Nat. Rev. Immunol. 19, 614\u2013625. https:\/\/doi.org\/10.1038\/s41577-019-0182-z (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"10895_CR30","doi-asserted-by":"publisher","first-page":"117321","DOI":"10.1016\/j.cca.2023.117321","volume":"543","author":"S Lin","year":"2023","unstructured":"Lin, S. et al. Decrease in cell counts and alteration of phenotype characterize peripheral NK cells of patients with anti-MDA5-positive dermatomyositis. Clin. Chim. Acta. 543, 117321. https:\/\/doi.org\/10.1016\/j.cca.2023.117321 (2023).","journal-title":"Clin. Chim. Acta."},{"key":"10895_CR31","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1002\/art.42264","volume":"74","author":"Y Ye","year":"2022","unstructured":"Ye, Y. et al. Two distinct immune cell signatures predict the clinical outcomes in patients with amyopathic dermatomyositis with interstitial lung disease. Arthritis Rheumatol. 74, 1822\u20131832. https:\/\/doi.org\/10.1002\/art.42264 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"10895_CR32","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.jaci.2021.07.022","volume":"148","author":"G Leem","year":"2021","unstructured":"Leem, G. et al. Abnormality in the NK-cell population is prolonged in severe COVID-19 patients. J. Allergy Clin. Immunol. 148, 996\u20131006. https:\/\/doi.org\/10.1016\/j.jaci.2021.07.022 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"10895_CR33","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.immuni.2006.08.009","volume":"25","author":"K Honda","year":"2006","unstructured":"Honda, K., Takaoka, A. & Taniguchi, T. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity 25, 349\u2013360. https:\/\/doi.org\/10.1016\/j.immuni.2006.08.009 (2006).","journal-title":"Immunity"},{"key":"10895_CR34","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.4049\/jimmunol.179.6.3434","volume":"179","author":"PI Osterlund","year":"2007","unstructured":"Osterlund, P. I., Pietil\u00e4, T. E., Veckman, V., Kotenko, S. V. & Julkunen, I. IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes. J. Immunol. 179, 3434\u20133442. https:\/\/doi.org\/10.4049\/jimmunol.179.6.3434 (2007).","journal-title":"J. Immunol."},{"key":"10895_CR35","doi-asserted-by":"publisher","first-page":"193","DOI":"10.55563\/clinexprheumatol\/9s7djz","volume":"43","author":"M Faria","year":"2025","unstructured":"Faria, M. et al. Different phenotypic manifestations between Brazilian and Japanese anti-MDA5 antibody-positive dermatomyositis: an international tricentric longitudinal study. Clin. Exp. Rheumatol. 43, 193\u2013201. https:\/\/doi.org\/10.55563\/clinexprheumatol\/9s7djz (2025).","journal-title":"Clin. Exp. Rheumatol."},{"key":"10895_CR36","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1378\/chest.10-0180","volume":"138","author":"GR Connors","year":"2010","unstructured":"Connors, G. R., Christopher-Stine, L., Oddis, C. V. & Danoff, S. K. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?. Chest 138, 1464\u20131474. https:\/\/doi.org\/10.1378\/chest.10-0180 (2010).","journal-title":"Chest"},{"key":"10895_CR37","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1183\/13993003.00150-2015","volume":"46","author":"A Fischer","year":"2015","unstructured":"Fischer, A. et al. An official European Respiratory Society\/American Thoracic Society research statement: Interstitial pneumonia with autoimmune features. Eur. Respir. J. 46, 976\u2013987. https:\/\/doi.org\/10.1183\/13993003.00150-2015 (2015).","journal-title":"Eur. Respir. J."},{"key":"10895_CR38","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg, M. C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 40, 1725. https:\/\/doi.org\/10.1002\/art.1780400928 (1997).","journal-title":"Arthritis Rheum."},{"key":"10895_CR39","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","volume":"78","author":"M Aringer","year":"2019","unstructured":"Aringer, M. et al. 2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann. Rheum. Dis. 78, 1151\u20131159. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214819 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"10895_CR40","first-page":"288","volume":"29","author":"DD Gladman","year":"2002","unstructured":"Gladman, D. D., Iba\u00f1ez, D. & Urowitz, M. B. Systemic lupus erythematosus disease activity index 2000. J. Rheumatol. 29, 288\u2013291 (2002).","journal-title":"J. Rheumatol."},{"key":"10895_CR41","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1056\/NEJMcp2009249","volume":"383","author":"RT Gandhi","year":"2020","unstructured":"Gandhi, R. T., Lynch, J. B. & Del Rio, C. Mild or moderate covid-19. N. Engl. J. Med. 383, 1757\u20131766. https:\/\/doi.org\/10.1056\/NEJMcp2009249 (2020).","journal-title":"N. Engl. J. Med."},{"key":"10895_CR42","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1080\/14397595.2018.1452179","volume":"29","author":"T Gono","year":"2019","unstructured":"Gono, T., Okazaki, Y., Murakami, A. & Kuwana, M. Improved quantification of a commercial enzyme-linked immunosorbent assay kit for measuring anti-MDA5 antibody. Mod. Rheumatol. 29, 140\u2013145. https:\/\/doi.org\/10.1080\/14397595.2018.1452179 (2019).","journal-title":"Mod. Rheumatol."},{"key":"10895_CR43","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/mr\/roac056","volume":"33","author":"M Kuwana","year":"2023","unstructured":"Kuwana, M. & Okazaki, Y. A multianalyte assay for the detection of dermatomyositis-related autoantibodies based on immunoprecipitation combined with immunoblotting. Mod. Rheumatol. 33, 543\u2013548. https:\/\/doi.org\/10.1093\/mr\/roac056 (2023).","journal-title":"Mod. Rheumatol."},{"key":"10895_CR44","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nri3158","volume":"12","author":"HT Maecker","year":"2012","unstructured":"Maecker, H. T., McCoy, J. P. & Nussenblatt, R. Standardizing immunophenotyping for the human immunology project. Nat. Rev. Immunol. 12, 191\u2013200. https:\/\/doi.org\/10.1038\/nri3158 (2012).","journal-title":"Nat. Rev. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10895-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10895-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10895-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T10:42:29Z","timestamp":1752576149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10895-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10895"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-10895-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"14 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T.G. has received speaking fees from Asahi Kasei Pharma, Astellas, Boehringer-Ingelheim, Bristol-Myers Squibb, Chugai, Eli Lily, Ono Pharmaceuticals, Pfizer, and Tanabe-Mitsubishi; M.K. has received royalties from MBL; speaking honoraria from Boehringer-Ingelheim; consulting honoraria from Argenx, AstraZeneca, Boehringer-Ingelheim, GSK, and Novartis; and research grants from Boehringer-Ingelheim and MBL. The other authors have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25537"}}